GSK vs ZBH
GSK plc vs Zimmer Biomet — AI-powered side-by-side comparison
GSK
GSK plc
64
Insufficient Data
VS
| Metric | GSK | ZBH |
|---|
| AI Score |
64
|
69
|
| Price |
$50.91
|
$97.22
|
| P/E Ratio |
15.80×
|
23.54×
|
| ROE |
35.0%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
73.3%
|
69.9%
|
| Debt / Equity |
1.03×
|
0.59×
|
| Dividend Yield |
3.5%
|
1.0%
|
| RSI (14) |
39.2
|
63.1
|
| Beta |
0.3
|
0.462
|
| Expected Upside |
—
|
+3.7%
|
AI Committee View
Current Innellis committee reasoning for GSK versus ZBH.
ZBH leads by 5 points.
ZBH scores 69/100 (Buy) versus GSK at 64/100 (Insufficient Data).
GSK Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- News sentiment is positive (+0.27 across 20 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical
ZBH Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical